Journal of tropical pediatrics · 2018
Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Shing-Yan Robert, Kwok Ka Li, Ng Daniel Kwok Keung, Hon Kam Lun
Аннотация
AIM: To evaluate the cost-effectiveness of palivizumab prophylaxis for premature infants born <29 weeks in Hong Kong.
METHOD: We evaluated the hospitalization rate for respiratory syncytial virus (RSV) infection within the first 12 months of discharge of a cohort of preterm infants born between 2010 and 2014 at two local hospitals.
RESULTS: In total, 40 of 135 infants were given palivizumab. The hospitalization rate for premature infants <29 weeks was reduced from 15.8 to 5% (p = 0.096) and that for infants <27 weeks was reduced from 33.3 to 8.7% (p = 0.046). In the former group, the incremental cost-effectiveness ratio per hospital admission prevented (ICER/HAP) was US dollar (USD) 24 365. In the latter subgroup, the ICER/HAP was USD 3108.
CONCLUSION: The cost-effectiveness as measured for infants <27 weeks is more favorable than that for infants <29 weeks.
METHOD: We evaluated the hospitalization rate for respiratory syncytial virus (RSV) infection within the first 12 months of discharge of a cohort of preterm infants born between 2010 and 2014 at two local hospitals.
RESULTS: In total, 40 of 135 infants were given palivizumab. The hospitalization rate for premature infants <29 weeks was reduced from 15.8 to 5% (p = 0.096) and that for infants <27 weeks was reduced from 33.3 to 8.7% (p = 0.046). In the former group, the incremental cost-effectiveness ratio per hospital admission prevented (ICER/HAP) was US dollar (USD) 24 365. In the latter subgroup, the ICER/HAP was USD 3108.
CONCLUSION: The cost-effectiveness as measured for infants <27 weeks is more favorable than that for infants <29 weeks.
Предметные рубрики MeSH
Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntiviral AgentsCohort StudiesCost of IllnessCost-Benefit AnalysisDrug CostsFemaleGestational AgeHong KongHospitalizationHumansImmunoglobulins, IntravenousInfant, NewbornInfant, PrematureIntensive Care UnitsLength of StayPalivizumabRespiratory Syncytial Virus InfectionsRespiratory Syncytial VirusesSeasonsTreatment Outcome